It's worth noting that the agreement has been forged a few months after Merck suffered a setback in its attempt to secure FDA approval for a potentially first-in-class drug for chronic cough ...

Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...